GlassScriptPhysician profile
Humza Omar Quadri
NPI 1457912255
$3,722.22
in general payments reported to CMS, 2019-2025
32 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.40 · 2023: $1,277 · 2024: $1,238 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.86 | 2023-2025 | |
| Novo Nordisk INC | $354.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $329.90 | 2022-2025 | |
| Lilly USA, LLC | $312.90 | 2023-2025 | Mounjaro, Zepbound, Taltz |
| Pfizer INC. | $235.82 | 2023-2025 | |
| Ucb, INC. | $167.47 | 2022-2024 | Cimzia |
| Amgen INC. | $148.93 | 2022-2025 | Prolia, Evenity, Avsola |
| Janssen Pharmaceuticals, INC | $139.52 | 2023-2024 | Spravato, Xarelto |
| Medtronic, INC. | $137.62 | 2023-2025 | Micra, Intellis Adaptivestim, Inceptiv |
| Merck Sharp & Dohme LLC | $134.08 | 2023-2025 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $131.67 | 2023-2025 | Saphnelo, Evusheld, Flumist Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $115.48 | 2023 | |
| Abiomed | $110.48 | 2025 | |
| Sobi, INC | $96.74 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.83 | 2023-2024 | Cyltezo, Jardiance, Ofev |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $70.10 | 2024-2025 | Vyepti, Rexulti |
| Glaxosmithkline, LLC. | $64.55 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Sandoz INC. | $61.40 | 2023-2024 | Hyrimoz |
| Solventum Corporation | $38.83 | 2025 | V.A.C. Veraflo, Prevena |
| E.R. Squibb & Sons, L.L.C. | $34.24 | 2023 | Eliquis |
| Ultragenyx Pharmaceutical INC. | $33.59 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.30 | 2024-2025 | Xifaxan |
| Depuy Synthes Sales INC. | $32.10 | 2024 | Orthovisc, Monovisc, Peak |
| Exact Sciences Corporation | $27.88 | 2023 | Cologuard Collection Kit |
| Globus Medical, INC. | $21.46 | 2025 | Senza |
| Genzyme Corporation | $19.41 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.22 | 2023 | |
| Janssen Biotech, INC. | $17.77 | 2024 | Tremfya |
| Idorsia Pharmaceuticals US INC | $17.20 | 2023 | Quviviq |
| Mylan Institutional INC. | $17.14 | 2023 | Hulio |
| Beta Bionics, INC. | $13.83 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Biohaven Pharmaceutical Holding Company LTD. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humza Quadri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.